AbCellera Biologics
ABCL
129 hedge funds and large institutions have $280M invested in AbCellera Biologics in 2025 Q1 according to their latest regulatory filings, with 12 funds opening new positions, 32 increasing their positions, 51 reducing their positions, and 27 closing their positions.
3.51% more ownership
Funds ownership: 38.56% → 42.08% (+3.5%)
12% less funds holding
Funds holding: 146 → 129 (-17)
16% less capital invested
Capital invested by funds: $334M → $280M (-$53.8M)
26% less call options, than puts
Call options by funds: $682K | Put options by funds: $927K
37% less repeat investments, than reductions
Existing positions increased: 32 | Existing positions reduced: 51
56% less first-time investments, than exits
New positions opened: 12 | Existing positions closed: 27
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS AM
Chicago,
Illinois
|
+$32M |
| 2 |
Capital World Investors
Los Angeles,
California
|
+$15.6M |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$8.91M |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$3.49M |
| 5 |
Renaissance Technologies
New York
|
+$1.17M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PM
Prosight Management
Dallas,
Texas
|
-$13M |
| 2 |
Baillie Gifford & Co
Edinburgh,
United Kingdom
|
-$2.98M |
| 3 |
OM
Opaleye Management
Boston,
Massachusetts
|
-$2.83M |
| 4 |
Norges Bank
Oslo,
Norway
|
-$1.87M |
| 5 |
Millennium Management
New York
|
-$1.76M |
ABCL Hedge Fund Activity: Q1 2025 in Review
129 of the 7,471 institutional investors tracked by Wall St. Rank reported a position in AbCellera Biologics (ABCL) for Q1 2025, worth a combined $280M — down 16% from $334M a quarter earlier.
Sellers outnumbered buyers: 27 funds closed out of ABCL and 12 opened new positions — a net loss of 15 holders — while 51 trimmed existing stakes and 32 added.
The largest buyer was UBS AM, adding an estimated $32M. The largest seller was Prosight Management, cutting an estimated $13M.
- 129 institutional investors held AbCellera Biologics (ABCL) as of Q1 2025, down from 146 in Q4 2024.
- Funds reported $280M of AbCellera Biologics stock for Q1 2025, down 16% quarter-over-quarter.
- 12 funds opened new AbCellera Biologics positions in Q1 2025 and 27 closed out, a net change of -15 holders.
- The largest AbCellera Biologics buyer in Q1 2025 was UBS AM, an estimated $32M added.
- The largest AbCellera Biologics seller in Q1 2025 was Prosight Management, an estimated $13M sold.
Based on aggregated 13F filings for Q1 2025.